Literature DB >> 9807728

Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas.

M Castagnaro1, C Casalone, E Bozzetta, R De Maria, B Biolatti, M Caramelli.   

Abstract

To investigate whether the degree of differentiation in feline mammary carcinoma (FMC) can indicate the post-surgical survival time (PST), tumours were surgically resected from 55 cats and histologically graded according to a method derived from human breast cancer studies. One year after the resection, 26 cats (47.3%) were alive while 29 (52.7%) had died as a consequence of FMC. Formalin-fixed, paraffin wax-embedded sections stained with haematoxylin and eosin were used to classify the FMCs initially, according to the WHO system. Histological grading was then performed on the basis of three main features: degree of tubule formation, nuclear and cellular pleomorphism, and accurate mitotic count obtained from a defined area. Immunohistochemical examination with an anti-actin antibody was used for the accurate detection of "in situ" carcinomas. Age and histological type were not significantly correlated with the PST. Seven tumours (12.7%) were graded as well-differentiated carcinoma (WDC; grade I), 33 (60%) as moderately differentiated carcinoma (MDC; grade II), and 15 (27.3%) as poorly differentiated carcinoma (PDC; grade III). The tumour-related death rates after the first post-surgical year were 0 in cats with WDC, 14 (42.4%) in those with MDC, and 15 (100%) in those with PDC. Six cats with tumours showing extensive myoepithelial differentiation were all alive after 1 post-surgical year. The grading system seemed to have a good predictive value in respect of grades I and III of FMC but not for grade II. Myoepithelial differentiation may be relevant to clinical prognosis in FMC.

Entities:  

Mesh:

Year:  1998        PMID: 9807728     DOI: 10.1016/s0021-9975(98)80049-2

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  11 in total

1.  Cutaneous metastases of a mammary carcinoma in a llama.

Authors:  T L Leichner; O Turner; G L Mason; G M Barrington
Journal:  Can Vet J       Date:  2001-03       Impact factor: 1.008

2.  Is melatonin of value in cancer treatment? Experience with a case of feline mammary carcinoma.

Authors:  Beverly Baxter
Journal:  Can Vet J       Date:  2017-07       Impact factor: 1.008

3.  Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions.

Authors:  Giovanni P Burrai; Sulma I Mohammed; Margaret A Miller; Vincenzo Marras; Salvatore Pirino; Maria F Addis; Sergio Uzzau; Elisabetta Antuofermo
Journal:  BMC Cancer       Date:  2010-04-22       Impact factor: 4.430

4.  Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.

Authors:  David A Wiese; Tuddow Thaiwong; Vilma Yuzbasiyan-Gurkan; Matti Kiupel
Journal:  BMC Cancer       Date:  2013-09-03       Impact factor: 4.430

5.  Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas.

Authors:  Lorella Maniscalco; Yolanda Millán; Selina Iussich; Mauro Denina; Raquel Sánchez-Céspedes; Francesca Gattino; Bartolomeo Biolatti; Nobuo Sasaki; Takayuki Nakagawa; Maria Flavia Di Renzo; Juana Martín de Las Mulas; Raffaella De Maria
Journal:  BMC Vet Res       Date:  2013-04-15       Impact factor: 2.741

6.  Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study.

Authors:  Javier Ordás; Yolanda Millán; Rafaela Dios; Carlos Reymundo; Juana Martín de Las Mulas
Journal:  BMC Cancer       Date:  2007-09-20       Impact factor: 4.430

7.  Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer.

Authors:  Diego Caliari; Valentina Zappulli; Roberta Rasotto; Barbara Cardazzo; Federica Frassineti; Michael H Goldschmidt; Massimo Castagnaro
Journal:  BMC Vet Res       Date:  2014-09-25       Impact factor: 2.741

8.  TiHo-0906: a new feline mammary cancer cell line with molecular, morphological, and immunocytological characteristics of epithelial to mesenchymal transition.

Authors:  José Luis Granados-Soler; Johannes Junginger; Marion Hewicker-Trautwein; Kirsten Bornemann-Kolatzki; Julia Beck; Bertram Brenig; Daniela Betz; Jan Torben Schille; Hugo Murua Escobar; Ingo Nolte
Journal:  Sci Rep       Date:  2018-09-05       Impact factor: 4.379

9.  Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.

Authors:  Elie Dagher; Violette Royer; Paul Buchet; Jérôme Abadie; Delphine Loussouarn; Mario Campone; Frédérique Nguyen
Journal:  BMC Cancer       Date:  2019-12-30       Impact factor: 4.430

10.  Analysis of Copy-Number Variations and Feline Mammary Carcinoma Survival.

Authors:  Hugo Murua Escobar; Ingo Nolte; José Luis Granados-Soler; Kirsten Bornemann-Kolatzki; Julia Beck; Bertram Brenig; Ekkehard Schütz; Daniela Betz; Johannes Junginger; Marion Hewicker-Trautwein
Journal:  Sci Rep       Date:  2020-01-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.